Trial Profile
Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome - Extension Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors SymBio Pharmaceuticals
- 19 Oct 2016 Status changed from recruiting to completed.
- 11 Dec 2013 New trial record